Advertisement
Research Article

The Association of Factor V Leiden and Prothrombin Gene Mutation and Placenta-Mediated Pregnancy Complications: A Systematic Review and Meta-analysis of Prospective Cohort Studies

  • Marc A. Rodger mail,

    mrodger@ohri.ca

    Affiliations: Thrombosis Program, Division of Hematology, Departments of Medicine, Obstetrics and Gynecology and Epidemiology/Community Medicine, University of Ottawa, Ottawa, Ontario, Canada, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada

    X
  • Marisol T. Betancourt,

    Affiliations: Thrombosis Program, Division of Hematology, Departments of Medicine, Obstetrics and Gynecology and Epidemiology/Community Medicine, University of Ottawa, Ottawa, Ontario, Canada, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada

    X
  • Peter Clark,

    Affiliation: Department of Transfusion Medicine, Ninewells, Hospital and Medical School, Dundee, United Kingdom

    X
  • Pelle G. Lindqvist,

    Affiliation: Department of Obstetrics and Gynecology, Karolinska Hospital, Huddinge, Sweden

    X
  • Donna Dizon-Townson,

    Affiliation: National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Bethesda, Maryland

    X
  • Joanne Said,

    Affiliations: Department of Perinatal Medicine, The Royal Women's Hospital, Carlton, Victoria Australia, Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia

    X
  • Uri Seligsohn,

    Affiliation: The Amalia Biron Thrombosis and Hemostasis Research Institute, the Chaim Sheba Medical Center, Tel Hashomer, Israel

    X
  • Marc Carrier,

    Affiliations: Thrombosis Program, Division of Hematology, Departments of Medicine, Obstetrics and Gynecology and Epidemiology/Community Medicine, University of Ottawa, Ottawa, Ontario, Canada, Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada

    X
  • Ophira Salomon,

    Affiliation: The Amalia Biron Thrombosis and Hemostasis Research Institute, the Chaim Sheba Medical Center, Tel Hashomer, Israel

    X
  • Ian A. Greer

    Affiliation: Hull York Medical School, York, United Kingdom

    X
  • Published: June 15, 2010
  • DOI: 10.1371/journal.pmed.1000292

About the Authors

Marc A. Rodger, Marisol T. Betancourt, Marc Carrier
Thrombosis Program, Division of Hematology, Departments of Medicine, Obstetrics and Gynecology and Epidemiology/Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
Marc A. Rodger, Marisol T. Betancourt, Marc Carrier
Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada
Peter Clark
Department of Transfusion Medicine, Ninewells, Hospital and Medical School, Dundee, United Kingdom
Pelle G. Lindqvist
Department of Obstetrics and Gynecology, Karolinska Hospital, Huddinge, Sweden
Donna Dizon-Townson
National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Bethesda, Maryland
Joanne Said
Department of Perinatal Medicine, The Royal Women's Hospital, Carlton, Victoria Australia
Joanne Said
Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia
Uri Seligsohn, Ophira Salomon
The Amalia Biron Thrombosis and Hemostasis Research Institute, the Chaim Sheba Medical Center, Tel Hashomer, Israel
Ian A. Greer
Hull York Medical School, York, United Kingdom

Corresponding Author

Email: mrodger@ohri.ca

Competing Interests

MAR is the principal investigator of a Canadian Institutes of Health Research randomised trial comparing dalteparin to no dalteparin to prevent placenta-mediated pregnancy complications in thrombophilic women. MAR has received grant funding from Pfizer, Sanofi, Boehringer Ingelheim, Bayer, GTC Therapeutics, and Leo Pharma. MAR has also served on advisory boards for Boehringer Ingelheim and Biomerieux but not been paid. IAG has received Honoraria for lectures and advisory boards from Sanofi Aventis and Leo Pharma.

Author Contributions

ICMJE criteria for authorship read and met: MAR MTB PC PGL DDT JS US MC OS IAG. Agree with the manuscript's results and conclusions: MAR MTB PC PGL DDT JS US MC OS IAG. Designed the experiments/the study: MAR MTB DDT IAG. Analyzed the data: MAR MTB DDT. Collected data/did experiments for the study: MAR MTB PC PGL DDT JS US OS IAG. Enrolled patients: MAR DDT JS US OS IAG. Wrote the first draft of the paper: MAR MTB MC. Contributed to the writing of the paper: MAR MTB PC PGL DDT JS MC IAG. Wrote the final version of the study protocol: MAR. Designed search strategy, conducted literature searches, and extracted data: MTB. Critical revising and final approval of the paper: PGL.